Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,